Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/365—Lactones
  • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K47/40—Cyclodextrins; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0043—Nose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/08—Solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications

Definitions

• the invention relates to salvinorin compositions and uses thereof. Specifically, the invention relates to administering salvinorin compositions to treat diseases and disorders associated with vasoconstriction, vaso-occlusion, or disruption of blood flow and autoregulation.
• salvinorin compositions may be administered to subjects with cardiac arrest, subarachnoid hemorrhage, stroke, cerebral vascular spasm, cerebral hypoxia/ischemia, cerebral artery occlusion, or any condition involved in autoregulation impairment.
• Salvinorin A is an active component of Salvia divinorum, a perennial herb of the Lamiaceae (mint) family, indigenous to Mexico. Salvia divinorum has long been traditionally used to produce visionary states of consciousness during spiritual healing sessions for religious purposes. It has been shown that salvinorin A is the most highly efficacious, naturally-occurring, nonpeptide, and the only non-nitrogenous kappa opioid receptor (KOR) agonist.
• KOR non-nitrogenous kappa opioid receptor
• Salvia divinorum as a naturally abundant plant has been used by human beings for recreational purposes for several centuries, and it has been proposed that salvinorin A could be a potential new opioid receptor agonist to be used in clinical practice, i.e. to treat depression or addiction etc. None of the other opioid KOR agonists have been used clinically so far because of their side effects. These include induction of significant dysphoria, low selectivity, respiratory depression, and unknown safety profiles. Salvinorin A does not belong to opioids despite being a KOR agonist, and it is not a controlled substance in most countries. Many intrinsic characters of the compound, i.e. quick onset, short acting, readily cross the blood brain barrier, and no respiratory depression, etc., make it an attractive possible medication, especially for neurological diseases.
• CA Cardiac arrest
• IR ischemia/reperfusion
• therapeutic hypothermia is considered the only effective post-CA treatment for neurological injuries.
• this treatment can only be applied to eligible patient populations and can be dangerous in under-resourced facilities, thereby leading to, among other things, an increased incidence of mortality, multiple organ failure, pulmonary hypertension, and bleeding, Therefore, a significant medical need exists for an easily manageable medication to improve survival rate and reduce the burden of neuronal injury from CA.
• Stroke is a leading cause of death worldwide. Each year, about 795,000 people experience a new or recurrent stroke in the United States; every 40 seconds, someone in the U.S. has a stroke; every 4 minutes, someone dies from a stroke. Stroke is a leading cause of serious long-term disability. 87% of all strokes are ischemic when blood supply to the brain is interrupted, a typical example of ischemia/reperfusion (IR) organ injury. Many potential neuroprotectants that reduce such neuronal injuries in experimental animals have failed in clinical trials. Due to the narrow therapeutic window of stroke, a potential neuroprotectant has to be able to be delivered in a timely manner without significant barrier with quick onset time.
• IR ischemia/reperfusion
• SAH Subarachnoid hemorrhage
• Salvinorin A is a very hydrophobic molecule and is insoluble in water. Salvinorin A is soluble in known to be soluble in organic solvents like ethanol, DMSO, and acetone. However, these solvent are not suitable for routine clinical use, especially for intravenous (IV) delivery. Since salvinorin A is useful clinically, for neurological disorders, there is a need to identify materials, preferably FDA approved materials, which can be used to formulate salvinorin A for clinical delivery.
• provided herein are methods of treating neurological injuries associated with cardiac arrest in a subject suffering from or having suffered cardiac arrest, the methods comprising: administering to said subject a therapeutically effective amount of salvinorin or a pharmaceutical composition thereof.
• methods of increasing the likelihood of survival in a subject suffering from or having suffered cardiac arrest comprising: administering to said subject a therapeutically effective amount of salvinorin or a pharmaceutical composition thereof.
• kits for treating cerebral vasospasm in a subject with a subarachnoid hemorrhage comprising: administering to said subject a therapeutically effective amount of salvinorin or a pharmaceutical composition thereof.
• a cerebral artery occlusion in a subject suffering from or having suffered a cerebral artery occlusion comprising: administering to said subject a therapeutically effective amount of salvinorin or a pharmaceutical composition thereof.
• provided herein are methods of reducing infarct size in a subject suffering from or having suffered a cerebral hypoxic/ischemic insult, the methods comprising: administering to said subject a therapeutically effective amount of salvinorin or a pharmaceutical composition thereof.
• methods of reducing vascular leakage in a subject suffering from or having suffered a cerebral hypoxia/ischemia the methods comprising: administering to said subject a therapeutically effective amount of salvinorin or a pharmaceutical composition thereof.
• compositions of salvinorin A comprising: an aqueous solution of salvinorin A and a cyclodextrin.
• compositions comprising: salvinorin for use in the methods described herein.
• FIG. 1 Salvinorin A dilated the pial artery of piglet.
• Panel A Salvinorin A dose- dependently dilated brain pial artery.
• L-NNA a Nitric Oxide Synthase Inhibitor, blocks the dilation effects of salvinorin but not SNP.
• Panel B Salvinorin A administration per 2 minutes can sustain the pial artery dilatation.
• Panel C 7-NINA the nNOS inhibitor did not block the dilation effects of salvinorin.
• L-NNA N(G)-nitro-L-arginine; SNP: sodium nitroprusside; 7-NINA: 7- nitroindazole.
• FIG. 4 Glibencamide, but not iberiotoxin, blocks the dilation effects of cromakalim and CGRP. Iberiotoxin but not glibencamide block the dilation effects of NS1619.
• Panel A demonstrates the effects of 10 nM of cromakalim, CGRP and NS1619, in the presence or absence of the pretreatment agents.
• Glib glibencamide; Iberi: Iberiotoxin; CGRP: calcitonin-gene related polypeptide; *: the agent administered first.
• FIG. 1 Naloxone and norbinaltrophimine but not sulpiride block the dilation effects of salvinorin A.
• Panel A Naloxone and Met-enkaphlin but not isoprotenol block the dilation effects of salvinorin A.
• Panel B norbinaltrophimine block the dilation effects of salvinorin A.
• Met-enk methionine enkephalin.
• Figure 8 is an image of salvinorin A.
• Figure 9 is an image of cucurbituril.
• Figure 10 is an image of salvinorin-cucurbituril complex.
• Figure 11 is an image of salvinorin-cucurbituril complex.
• Figure 12 is an image of a salvinorin-cucurbituril complex.
• FIG. 13 Effects of post HI salvinorin A administration on pial artery dilation to hypercapnia.
• HI with DMSO impaired dilation of pial artery to hypercapnia.
• Percentage change (diameter after hypercapnia- diameter before hypercapnia)/diameter before hypercapnia) x 100.
• SA Salvinorin A; Moderate: hypercapnia with PaC0 2 of 50 to 60 mmHg; Severe: hypercapnia with PaC0 2 of 70 to 80 mmHg.
• Figure 14 Effects of post HI salvinorin A administration on pial artery dilation to hypotension.
• HI with DMSO damaged dilation of pial artery to hypotension.
• SA administrated at onset and 30 min after HI preserved the dilations of pial artery to moderate and severe hypotension, which were blunted by co-administration of norbinaltorphimine (Norbin).
• Percentage change (diameter after hypotension- diameter before hypotension) / diameter before hypotension) x 100.
• N 5 in each group.
• SA Salvinorin A.
• Moderate 25% decrease of mean blood pressure.
• Severe 45% decrease of mean blood pressure.
• Figure 17 Effects of hypotension on pial artery diameter before (baseline), after hypoxia/ischemia (H/I; P02 of 35 mm Hg for 10 minutes followed by global cerebral ischemia for 20 minutes), after H/I pretreated with salvinorin A (10 ⁇ g/kg i.v.; H/I+SA) 30 minutes before H/I, and after H/I pretreated with U0126 (lmg/kg, i.v.; H/I+SA+U0126), the antagonist of ERK,30 minutes before salvinorin A, SP600125 ( ⁇ ⁇ , administrated topically; H/I+SA+SP600125), the antagonist of JNK, 30 minutes before salvinorin A, SB203580 (10 ⁇ , administrated topically; H/I+SA+SB203580), the antagonist of P38, 30 minutes before salvinorin A.
• H/I hypoxia/ischemia
• Pretreatment with salvinorin A preserved the dilation response of pial artery to hypotension, which is abolished by U0126.
• SA Salvinorin A
• H/I Hypoxia/ischemia
• Moderate moderate hypotension (25 % decrease of MAP)
• Severe severe hypotension (45% decrease of MAP).
• N 5 each group; baseline bar represents the data from all 25 animals. All non-listed corrected P-values >0.405. All corrected 95% confidence interval width ⁇ 10.32.
• Figure 18 Effects of hypercarbia on pial artery diameter before (baseline), after hypoxia/ischemia (H/I; P02 of 35 mm Hg for 10 minutes followed by global cerebral ischemia for 20 minutes), after H/I pretreated with salvinorin A (10 ⁇ g/kg i.v.; H/I+SA) 30 minutes before H/I, and after H/I pretreated with U0126 (lmg/kg, i.v.; H/I+SA+U0126), the antagonist of ERK,30 minutes before salvinorin A, SP600125 ( ⁇ , administrated topically; H/I+SA+SP600125), the antagonist of JNK, 30 minutes before salvinorin A, SB203580 (10 ⁇ , administrated topically; H/I+SA+SB203580), the antagonist of P38, 30 minutes before salvinorin A.
• H/I hypoxia/ischemia
• P02 of 35 mm Hg for 10 minutes followed by global cerebral ischemia for 20 minutes
• U0126
• Pretreatment with salvinorin A preserved the dilation response of pial artery to hypercarbia, which is abolished by U0126.
• SA Salvinorin A
• H/I Hypoxia/ischemia
• Moderate moderate hypercapnia with PaC02 of 50 to 60 mmHg
• Severe severe hypercapnia with PaC02 of 70 to 80 mmHg.
• N 5 each group; baseline bar represents the data from all 25 animals. All non-listed corrected P-values >0.108. All corrected 95% confidence interval width ⁇ 10.43.
• FIG. 19 Effects of isoproterenol ( ⁇ , ⁇ ) on pial artery diameter before (baseline) and after hypoxia/ischemia did not change significantly in the presence and absence of various interventions.
• SA Salvinorin A
• H/I Hypoxia/ischemia.
• Figure 20 The ratio of pERK/ERK before administration of salvinorin A and 30 minutes after pretreatment of salvinorin A or U0126 plus salvinorin A.
• the ratio of pERK/ERK in CSF increased significantly 30 minutes in the salvinorin A pretreatment group; and such increase was abolished by the ERK antagonist (U0126) pretreatment SA: Salvinorin A.
• Figure 21 shows the mortality of different groups in Example 5.
• the mortality of HP and SA group is 70% and 38.5%, respectively. There was no death in the control group.
• Figure 22 shows that SA elevated the body weight gaining on postnatal day 2 and day 3 in Example 5.
• Body weight of pups in control, hypoxia, and SA treated groups on PI, P2, P3, P7, P14, and P21 were recorded in our study.
• P3, P7, P14 and P21 no significant difference was observed between different groups (data not shown) (*p ⁇ 0.05 SA+HP vs. HP.
• P postnatal
• SA Salvinorin A
• HP Hypoxia
• Figure 23 shows that SA improved some developmental neurological outcomes in Example 5. Hypoxia induced significant delay in forelimb grasping (A), cliff aversion (B), righting response (C), and eye opening (D). SA rescued such hypoxia induced neurological outcomes significantly (#p ⁇ 0.05 HP vs. Control; *p ⁇ 0.05 SA+HP vs. HP. SA: Salvinorin A; HP: Hypoxia).
• FIG. SA showed no statistical improvement on some of the development parameters in Example 5. There are no statistical significance on some of the development parameters such as walking (A), crawling (B), running (C), head point and sniffing (D), sitting (E), rearing with support (F), negative geotaxis test (G) and placing reflex (H), though hypoxic pups also showed delayed appearance compared to control and SA groups. Hypoxia pups showed delayed appearance of rearing without support at day 19.86+0.29 compared to day 18.18+0.4435 in control group. Hypoxic pups treated with SA presented better performance than hypoxic pups at day 18.69+0.3843(1), which is similar with control group (#p ⁇ 0.05 HP vs. Control; *p ⁇ 0.05 SA+HP vs. HP. SA: Salvinorin A; HP: Hypoxia).
• FIG. 25 SA did not improve the outcome of open field test significantly in Example 5.
• the left figure shows the sketch of the open field test. Mice were individually placed in a 41cm (L) x 41 cm (W) x 30cm (H) plastic box. "Central part of the area” was defined as a 20.5cm x 20.5cm square in the center of the box. The rest of the area was defined as "peripheral part of the area”. The time each mouse spent on exploring the central part and periphery part of the area and the number of rearing behavior were recorded respectively in the first 5 minutes and 30 minutes.
• Figure 26 shows that SA improved rearing activity at P21 significantly in Example 5. Rearing test at P21 in the first 5 min and 30 min was impaired by hypoxia and such impairment was not observed with SA administration which was similar to the control group, indicating that SA could improve some of the hypoxia induced long term neurological deficit (#p ⁇ 0.05 HP vs. Control; *p ⁇ 0.05 SA+HP vs. HP. P: postnatal; SA: Salvinorin A; HP: Hypoxia).
• FIG 27 shows that SA did not improve the long term anxiety level and spatial memory in Example 5.
• the elevated zero maze to detect the anxiety level and locomotor activity there were no significant differences in the percentage of time spent in the open arm (A) and open/closed transitions (B) of the maze between SA administration and hypoxia alone groups .
• the Barnes maze task was used to assess spatial reference memory.
• SA Salvinorin A
• HP Hypoxia
• FIG 28 shows that SA did not change the long term memory deficit in Example 5. All groups learned at similar rates and there was no significant difference in the long-term behavior of fear conditioning test. Control group showed no impairment compared to HP group in the training trial (A), cued trial (B), short term (C) and long term (D) contextual freezing behavior (p > 0.05). Pretreatment with SA did not change the fear memory compared with HP and Control mice (p > 0.05.
• SA Salvinorin A; HP: Hypoxia).
• Figure 29 depicts the protocol used in the mouse study of Example 6.
• Figure 30 shows that intranasal salvinorin A administration demonstrated dose- dependent improvements in motor function as measured by a grip strength score. However, such protective effects diminish beyond the dose of 250 g/kg.
• Figure 31 shows that intranasal salvinorin A administration demonstrated dose- dependent improvements in neurobehavior.
• Figure 32 shows that intranasal salvinorin A administration demonstrated dose-dependent reduction in infarct size as can be seen by the reduction of white infarcted area in TTC stains of the brain. Similar to the results indicated in figure 30, the protective effects diminish beyond the dose of 250 ⁇ g kg.
• Figure 33 shows the infarcted area as a function of the dose of intranasal salvinorin A administered.
• FIG. 34 Evans blue extravasation indicated blood brain barrier disruption and vascular leakage after ischemia and reperfusion of the brain. Intranasal salvinorin A administration reduced the disruption and leakage, while the administration of the kappa receptor antagonist
• Norbinaltorphimine inhibited the protective effect of salvinorin A.
• Figure 35 shows that intranasal salvinorin A improves overall motor function.
• the mouse that has not been administered salvinorin A (the mouse on the ground) cannot walk normally since the left side was paralyzed 24 hours after 120 min of middle cerebral artery occlusion
• MCAO intranasal salvinorin A after the injury (the mouse on the string) can crawl over a hanging string.
• Figure 36 Affinity determination for herkinorin in HEK cells over-expressed with mu and kappa opioid receptor.
• Figure 36A demonstrates the binding affinity of herkinorin with the mu receptor as compared to DAMGO, a potent mu agonist. The K; is 2.5 nM for DAMGO and 45 nM for herkinorin.
• the model illustrated in figure 36B suggests that herkinorin (labeled as H over the red sphere ligand in the binding pocket) binds to the same binding site as that for ⁇ -funaltrexamine (labeled as ⁇ over the light blue sphere ligand in the binding pocket), a selective mu opioid receptor ligand found in the crystal structure.
• Figure 37 Affinity determination for herkinorin in HEK cells over-expressed with kappa opioid receptor and the location of the binding site.
• Figure37A demonstrates the binding affinity of herkinorin with kappa receptor as compare to U69593, a potent kappa agonist.
• the K is 0.8 nM for U69593 and 184 nM for herkinorin.
• the model illustrated in figure 37B suggests that herkinorin (labeled as H over the red sphere ligand in the binding pocket) binds to the same binding site as that for JDTic (labeled as J over the green sphere ligand in the binding pocket), a selective kappa opioid receptor ligand found in the crystal structure.
• Figure 38 The cerebrovasodilation effects of herkinorin is mediated though kappa opioid receptor.
• Figure 38 demonstrates the dilatation effect of herkinoin (Herk) on pial artery is blocked by the kappa receptor antagonist norbinaltorphimine (NTP) (figure 38A); but not blocked by the mu receptor antagonist ⁇ -funaltrexamine ( ⁇ -FNA, figure 38B).
• NTP norbinaltorphimine
• ⁇ -FNA mu receptor antagonist
• the dilatation effect of herkinoin is equvelent to that of isoproterenol (ISO), a potent beta adrenergic agonist (figure 38A)( Ps>0.05).
• NTP or ⁇ -FNA alone does not have any dilatation effects (One way Anova followed by Dunnett's multipal comparison tests).
• n 5 for each group. *for p ⁇ 0.05, **for p ⁇ 0.01, ***for p ⁇ 0.005 in t-tests, and #for p ⁇ 0.05 in ANOVA tests.
• FIG 39 Cerebrovasodilation effects of herkinorin is mediated via cAMP signaling.
• Figure 39 A demonstrates that the levels of cAMP in CSF elevated with herkinorin administration, which were abolished with administration of the kappa antagonist NTP.
• FIG 40 Whole brain images (Ventral) after 24 hours for Sham, subarachnoid hemorrhage (SAH) and Salvanorin A (SA) treatment groups.
• FIG 41 H&E staining of basil artery of Sham, SAH and SA treatment groups.
• FIG. 42 Salvinorin A given after SAH (A) increased the diameter and (B) decreased the thickness of the wall of the basil artery significantly 24 hours after SAH. (C) Salvinorin A given after SAH has no significant effect on the neurological score # p ⁇ 0.05 vs. Sham, *p ⁇ 0.05 vs.SAH
• Figure 43 Standard curve for Salvinorin A in methanol- acetone (4: 1).
• the invention relates to salvinorin compositions and uses thereof. Specifically, the invention relates to administering salvinorin to increase survival of a subject following cardiac arrest or stroke in that subject. The invention further relates to treating a subject with cerebral vascular spasm, a subarachnoid hemorrhage, cerebral hypoxia/ischemia, cerebral artery occlusion, or any condition involved in autoregulation impairment.
• provided herein are methods of treating neurological injuries associated with cardiac arrest in a subject suffering from or having suffered cardiac arrest, the methods comprising: administering to said subject a therapeutically effective amount of salvinorin or a pharmaceutical composition thereof.
• methods of increasing the likelihood of survival in a subject suffering from or having suffered cardiac arrest the methods comprising: administering to said subject a therapeutically effective amount of salvinorin or a pharmaceutical composition thereof.
• methods of treating cerebral vasospasm in a subject with a subarachnoid hemorrhage the methods comprising: administering to said subject a therapeutically effective amount of salvinorin or a pharmaceutical composition thereof.
• a cerebral artery occlusion in a subject suffering from or having suffered a cerebral artery occlusion comprising: administering to said subject a therapeutically effective amount of salvinorin or a pharmaceutical composition thereof.
• provided herein are methods of reducing infarct size in a subject suffering from or having suffered a cerebral hypoxia/ischemia, the methods comprising: administering to said subject a therapeutically effective amount of salvinorin or a pharmaceutical composition thereof.
• methods of reducing vascular leakage in a subject suffering from or having suffered a cerebral hypoxia/ischemia comprising: administering to said subject a therapeutically effective amount of salvinorin or a pharmaceutical composition thereof.
• compositions comprising salvinorin for use in the methods described herein.
• provided herein are methods for producing cerebrovasodilation in a subject in need thereof, the methods comprising: administering to said subject a therapeutically effective amount of salvinorin or a pharmaceutical composition thereof.
• methods for treating a disease associated with cerebrovasospasm, hypoxia, and/or ischemia in a subject the method comprising: administering to said subject a therapeutically effective amount of salvinorin or a pharmaceutical composition thereof.
• provided herein are methods for treating a disease associated with vasoconstriction, vaso-occlusion, or disruption of blood flow and autoregulation in a subject, the methods comprising: administering to said subject a therapeutically effective amount of salvinorin or a pharmaceutical composition thereof.
• methods for producing a sedative or anesthetic effect in a subject in need thereof comprising: administering to said subject a therapeutically effective amount of salvinorin or pharmaceutical composition thereof.
• compositions comprising: a therapeutically effective amount of salvinorin, wherein said salvinorin is present in an amount effective to produce cerebrovasodilation in a subject in need thereof.
• pharmaceutical compositions comprising: a therapeutically effective amount of salvinorin, wherein said salvinorin is present in an amount effective to treat a disease associated with cerebrovasospasm, hypoxia, and/or ischemia in a subject.
• pharmaceutical compositions comprising: a therapeutically effective amount of salvinorin to treat cerebral vasospasm in a subject with a subarachnoid hemorrhage.
• compositions comprising: a therapeutically effective amount of salvinorin, wherein said salvinorin is present in an amount effective to provide organ protection from hypoxia/ischemia in a subject.
• pharmaceutical compositions comprising: a therapeutically effective amount of salvinorin, wherein said salvinorin is present in an amount effective to treat a disease associated with vasoconstriction, vaso- occlusion, or disruption of blood flow and autoregulation in a subject.
• compositions comprising: a therapeutically effective amount of salvinorin, wherein said salvinorin is present in an amount effective to produce a sedative or antinociceptive effect in a subject in need thereof.
• compositions of salvinorin A comprising: an aqueous solution of salvinorin A and a cyclodextrin.
• the cyclodextrin is a 2-hydroxypropyl-cyclodextrin, such as 2-hydroxypropyl- - cyclodextrin (HPBCD) or 2-hydroxypropyl-y-cyclodextrin (HPGCD). More preferably, the cyclodextrin is 2-hydroxypropyl-P -cyclodextrin (HPBCD).
• the composition is adapted for intravenous administration.
• the salvinorin A concentration is at least 25 ⁇ g/mL.
• the salvinorin A concentration is at least 50 ⁇ g/mL.
• the cyclodextrin (e.g. , HPBCD) concentration in the aqueous salvinorin A solution is at least 1 % (w/v), at least 2.5% (w/v), at least 5% (w/v), at least 7.5%
• the cyclodextrin (e.g. , HPBCD) concentration in the aqueous salvinorin A solution is less than 50% (w/v), less than 45% (w/v), less than 40% (w/v), less than 35% (w/v), less than 30% (w/v), less than 25% (w/v), less than 22.5% (w/v), less than 20% (w/v), less than 17.5% (w/v), less than 15% (w/v).
• the cyclodextrin is HPBCD with a concentration in the aqueous salvinorin A solution of aboutt least 20% (w/v).
• the inventor of the instant application surprisingly and unexpectedly found that salvinorin dilates cerebral vessels dramatically with rapid onset and offset, and without a change in hemodynamics.
• the diameter of the cerebral artery dilated up to 40% with 1 micromolar salvinorin as shown in Figure 7.
• the vessels dilated immediately after application of salvinorin and the dilation effect lasted less than 3 to 5 minutes.
• salvinorin can be used to treat cerebral vascular spasm in stroke, brain injury, or other related clinical situations associated with cerebral vascular spasm, including post subarachnoid hemorrhage and head trauma.
• salvinorin may be used to treat towards spinal cord ischemia and other nerve ischemia.
• Salvinorin A and its analogues are known compounds.
• Salvinorin A the active component of Salvia divinorum, which is used by nearly a million people for recreational purposes annually in United States, is the only known non-nitrogenous selective kappa opioid receptor (KOR) agonist.
• KOR kappa opioid receptor
• a diterpene salvinorin A has been shown to be a high affinity and selective kappa opioid receptor agonist. See Roth et al , Proc. Natl. Acad. Sci. USA 99: 11934 (2002); and Butelman et al. , Psychopharmacology 172:220 (2004).
• Salvinorins and their derivatives are known in the art. For example, salvinorins, their derivatives, and methods for synthesizing them are described in U.S. 2006/0052439, U.S. 2007/0213394, WO 2005/089745, and WO2008/119097, each of which is incorporated by reference herein in its entirety.
• a salvinorin or its derivative may be used in the methods and compositions described herein.
• a salvinorin include, but are not limited to, salvinorin A, B, C, D, E, or F.
• salvinorin is salvinorin A.
• salvinorin B is salvinorin C.
• salvinorin is salvinorin D.
• salvinorin E is salvinorin E.
• salvinorin is salvinorin F.
• salvinorin is an ester of a salvinorin.
• salvinorin is a salvinorin benzoate.
• salvinorin is a metabolite of salvinorin.
• salvinorin is an analogue of salvinorin A.
• herkinorin an analogue of salvinorin A (Ji F, et ah , Brain Res. 2013, 1490:95-100, which is hereby incorporated by reference in its entirety).
• Other salvinorin analogues that may be used in the methods and compositions described herein are 2-0-ethoxymethylsalvinorin B and 2-0- methoxymethylsalvinorin B.
• administering a therapeutically effective amount of a salvinorin produces vasodilation in a subject in need thereof.
• the invention further provides methods of treating a disease or condition, comprising administering to a mammal in need thereof a therapeutically effective amount of salvinorin.
• methods for treating a disease associated with vasoconstriction, vaso-occlusion, or disruption of blood flow and autoregulation in a subject, the method comprising: administering to said subject a therapeutically effective amount of salvinorin or a pharmaceutical composition thereof.
• compositions described herein may include a "therapeutically effective amount.”
• a “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result.
• a therapeutically effective amount of a molecule may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the molecule to elicit a desired response in the individual.
• a therapeutically effective amount is also one in which toxic or detrimental effects of the molecule are outweighed by the therapeutically beneficial effects.
• treating neurological injuries associated with cardiac arrest includes, but is not limited to, preventing neurological injuries in a subject suffering from or having suffered cardiac arrest.
• Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of the extent of a disease or condition, stabilization of a disease or condition (i.e.
• Treatment can also mean prolonging survival as compared to expected survival if not receiving treatment.
• Those in need of treatment include those already with the disease or condition as well as those prone to having the disease or condition or those in which the disease or condition is to be prevented.
• Examples of diseases or disorders caused by or otherwise associated with vasoconstriction, vaso-occlusion, or disruption of blood flow and autoregulation include, but are not limited to, a cerebral vascular spasm, a subarachnoid hemorrhage, a stroke, a brain trauma or injury, an ischemia reperfusion injury, low perfusion status, and hypoxia.
• the salvinorins and pharmaceutical compositions thereof described herein can administered to a subject by a method known in the art, such as parenterally, paracancerally, transmucosally, transdermally, intramuscularly, intravenously, intra-dermally, subcutaneously, intra-peritonealy, intra-ventricularly, intra-cranially, intra-vaginally or intra- tumorally, intrathecally, and inhalationally.
• they are administered transmucosally.
• they are administered intranasally.
• the pharmaceutical compositions are administered orally, and are thus formulated in a form suitable for oral administration, i.e. as a solid or a liquid preparation.
• suitable solid oral formulations include tablets, capsules, pills, granules, pellets and the like.
• Suitable liquid oral formulations include solutions, suspensions, dispersions, emulsions, oils and the like.
• the active ingredient is formulated in a capsule.
• the compositions of the present invention comprise, in addition to the active compound and the inert carrier or diluent, a hard gelating capsule.
• the pharmaceutical compositions are administered by intravenous, intra-arterial, or intra-muscular injection of a liquid preparation.
• suitable liquid formulations include solutions, suspensions, dispersions, emulsions, oils and the like.
• the pharmaceutical compositions are administered intravenously and are thus formulated in a form suitable for intravenous administration.
• the pharmaceutical compositions are administered intra- arterially and are thus formulated in a form suitable for intra-arterial administration.
• the pharmaceutical compositions are administered intra-muscularly and are thus formulated in a form suitable for intra-muscular administration.
• compositions are administered intranasally and are thus formulated in a form suitable for intranasal administration.
• the pharmaceutical compositions are administered topically to body surfaces and are thus formulated in a form suitable for topical administration.
• Topical formulations include gels, ointments, creams, lotions, drops and the like.
• the pharmaceutical composition is administered as a suppository, for example, a rectal suppository or a urethral suppository.
• the pharmaceutical composition is administered by subcutaneous implantation of a pellet.
• the pellet provides for controlled release of active agent over a period of time.
• the active compound is delivered in a vesicle, e.g. a liposome.
• carriers or diluents used in methods of the present invention include, but are not limited to, a gum, a starch (e.g. corn starch, pregeletanized starch), a sugar (e.g., lactose, mannitol, sucrose, dextrose), a cellulosic material (e.g. microcrystalline cellulose), an acrylate (e.g. polymethylacrylate), calcium carbonate, magnesium oxide, talc, or mixtures thereof.
• a gum e.g. corn starch, pregeletanized starch
• a sugar e.g., lactose, mannitol, sucrose, dextrose
• a cellulosic material e.g. microcrystalline cellulose
• an acrylate e.g. polymethylacrylate
• pharmaceutically acceptable carriers for liquid formulations are aqueous or non-aqueous solutions, suspensions, emulsions or oils.
• non-aqueous solvents are propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate.
• Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
• oils are those of animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, olive oil, sunflower oil, fish-liver oil, another marine oil, or a lipid from milk or eggs.
• parenteral vehicles for subcutaneous, intravenous, intra- arterial, or intramuscular injection
• parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's and fixed oils.
• Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like.
• sterile liquids such as water and oils, with or without the addition of a surfactant and other pharmaceutically acceptable adjuvants.
• water, saline, aqueous dextrose and related sugar solutions, and glycols such as propylene glycols or polyethylene glycol are preferred liquid carriers, particularly for injectable solutions.
• oils are those of animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, olive oil, sunflower oil, fish-liver oil, another marine oil, or a lipid from milk or eggs.
• compositions further comprise binders (e.g., acacia, cornstarch, gelatin, carbomer, ethyl cellulose, guar gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, povidone), disintegrating agents (e.g., binders, e.g., acacia, cornstarch, gelatin, carbomer, ethyl cellulose, guar gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, povidone), disintegrating agents (e.g.
• binders e.g., acacia, cornstarch, gelatin, carbomer, ethyl cellulose, guar gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, povidone
• disintegrating agents e.g.
• cornstarch potato starch, alginic acid, silicon dioxide, croscarmelose sodium, crospovidone, guar gum, sodium starch glycolate), buffers (e.g., Tris-HCI., acetate, phosphate) of various pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), protease inhibitors, surfactants (e.g., sodium lauryl sulfate), permeation enhancers, solubilizing agents (e.g., glycerol, polyethylene glycerol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite, butylated hydroxyanisole), stabilizers (e.g.
• viscosity increasing agents e.g. carbomer, colloidal silicon dioxide, ethyl cellulose, guar gum
• sweeteners e.g. aspartame, citric acid
• preservatives e.g., Thimerosal, benzyl alcohol, parabens
• lubricants e.g. stearic acid, magnesium stearate, polyethylene glycol, sodium lauryl sulfate
• flow-aids e.g. colloidal silicon dioxide
• plasticizers e.g. diethyl phthalate, triethyl citrate
• emulsifiers e.g.
• carbomer hydroxypropyl cellulose, sodium lauryl sulfate
• polymer coatings e.g., poloxamers or poloxamines
• coating and film forming agents e.g. ethyl cellulose, acrylates, polymethacrylates
• the pharmaceutical compositions provided herein are controlled-release compositions, i.e. compositions in which the active compound is released over a period of time after administration.
• Controlled- or sustained-release compositions include formulation in lipophilic depots (e.g. fatty acids, waxes, oils).
• the composition is an immediate-release composition, i.e. a composition in which of the active compound is released immediately after administration.
• the pharmaceutical composition is delivered in a controlled release system.
• the agent may be administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other modes of administration.
• a pump may be used (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)).
• polymeric materials are used; e.g. in microspheres in or an implant.
• a controlled release system is placed in proximity to the target cell, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984); and Langer R, Science 249: 1527-1533 (1990).
• compositions also include, in another embodiment, incorporation of the active material into or onto particulate preparations of polymeric compounds such as polylactic acid, polglycolic acid, hydrogels, etc, or onto liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts.)
• polymeric compounds such as polylactic acid, polglycolic acid, hydrogels, etc, or onto liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts.
• particulate compositions coated with polymers e.g. poloxamers or poloxamines
• polymers e.g. poloxamers or poloxamines
• Also comprehended by the invention are compounds modified by the covalent attachment of water-soluble polymers such as polyethylene glycol, copolymers of polyethylene glycol and polypropylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, cyclodextrin, cucurbituril, polyvinylpyrrolidone or polyproline.
• the modified compounds are known to exhibit substantially longer half-lives in blood following intravenous injection than do the corresponding unmodified compounds (Abuchowski et al., 1981; Newmark et al., 1982; and Katre et al., 1987).
• Such modifications may also increase the compound's solubility in aqueous solution, eliminate aggregation, enhance the physical and chemical stability of the compound, and greatly reduce the immunogenicity and reactivity of the compound.
• the desired in vivo biological activity may be achieved by the administration of such polymer-compound abducts less frequently or in lower doses than with the unmodified compound.
• the methods comprise administering an active compound as the sole active ingredient.
• methods for treating diseases and disorders that comprise administering the active compound in combination with one or more additional therapeutic agents. These additional agents are appropriate for the disease or disorder that is being treated, as is known in the art.
• the other therapeutically effective agent may be conjugated to the salvinorin, incorporated into the same composition as the salvinorin, or may be administered as a separate composition.
• the other therapeutically agent or treatment may be administered prior to, during and/or after the administration of the salvinorin.
• compositions described herein, for treatment of conditions or diseases as described herein vary depending upon many different factors, including means of administration, target site, physiological state of the patient, whether the patient is human or an animal, other medications administered, and whether treatment is prophylactic or therapeutic. Usually, the patient is a human but non-human mammals including transgenic mammals can also be treated. Treatment dosages may be titrated using routine methods known to those of skill in the art to optimize safety and efficacy.
• a single bolus may be administered.
• several divided doses may be administered over time.
• a dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation.
• Dosage unit form refers to physically discrete units suited as unitary dosages for treating mammalian subjects. Each unit may contain a predetermined quantity of active compound calculated to produce a desired therapeutic effect. In some embodiments, the dosage unit forms are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic or prophylactic effect to be achieved.
• the composition may be administered only once, or it may be administered multiple times or continuous infusion.
• the composition may be, for example, administered three times a day, twice a day, once a day, once every two days, twice a week, weekly, once every two weeks, or monthly.
• Dosage values may vary with the type and severity of the condition to be alleviated. It is further understood that for any particular subject, specific dosage regimens may be adjusted over time according to the individual need and the professional judgment of the person administering or supervising administration of the compositions, and that dosage ranges set forth herein are exemplary and are not intended to limit the scope or practice of the methods.
• administering to a subject is not limited to any particular delivery system and may include, without limitation, parenteral (including subcutaneous, intravenous, intramedullary, intraarticular, intramuscular, or intraperitoneal injection) rectal, topical, transdermal or oral (for example, in capsules, suspensions or tablets), intrathecal, intranasal and inhalational.
• Administration to a subject may occur in a single dose or in repeat administrations or continuous infusion, and in any of a variety of physiologically acceptable salt forms, and/or with an acceptable pharmaceutical carrier and/or additive as part of a pharmaceutical composition.
• physiologically acceptable salt forms and standard pharmaceutical formulation techniques are known to persons skilled in the art (see, for example, Remington's Pharmaceutical Sciences, Mack Publishing Co.).
• the term "about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviations, per practice in the art.
• a measurable value such as an amount, a temporal duration, a concentration, and the like, may encompass variations of ⁇ 20% or ⁇ 10%, more preferably ⁇ 5%, even more preferably ⁇ 1%, and still more preferably ⁇ 0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.
• the methods of treatment described herein can be used to treat a suitable mammal, including primates, such as monkeys and humans, horses, cows, cats, dogs, rabbits, and rodents such as rats and mice.
• a suitable mammal including primates, such as monkeys and humans, horses, cows, cats, dogs, rabbits, and rodents such as rats and mice.
• the mammal to be treated is human.
• Salvinorin A Produces Cerebrovasodilation throu2h Activation of Nitric Oxide Synthase, Kappa Receptor and Adenosine Triphosphate Sensitive Potassium Channel
• Salvinorin A purity >98%), sodium nitroprusside (SNP), N(G)-nitro-L-arginine (L- NNA), glibenclamide, iberiotoxin, cromakalim, calcitonin-gene related polypeptide (CGRP), NS 1619, naloxone, methionine enkephalin, norbinaltorphimine, 7-nitroindazole(7-NINA), sulpiride and isoproterenol are obtained from Sigma-Aldrich (St. Louis, MO, USA). All other chemicals were also obtained from Sigma and were of reagent grade. Animals and surgery
• Newborn pigs (1-6 days old, weighing 1.3-1.8 kg) of both genders were used for this study. Protocols were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania. The animals were induced with isoflurane (1-2 minimal alveolar concentration) and then maintained with alpha-chloralose (80-100mg/kg supplemented with 5mg/kg/h IV). Both femoral arteries were catheterized to monitor blood pressure and blood gas. A catheter was inserted into right femoral vein for medication administration. The animals were ventilated with room air after trachea cannulation. Rectal temperature was maintained at 37 - 39 °C by a heating pad. A closed cranial window was placed for direct pial artery visualization and diameter measurement.
• the closed cranial window consisted of three parts: a stainless steel ring, a circular glass cover-slip, and three ports consisting of 17-gauge hypodermic needles attached to three precut holes in the stainless steel ring.
• Cortical periarachnoid cerebrospinal fluid (CSF) was collected through the cranial window port for cyclic guanosine monophosphate (cGMP) determination.
• CSF Cortical periarachnoid cerebrospinal fluid
• cGMP cyclic guanosine monophosphate
• the space under the window was filled with artificial CSF with the following composition (in mM): 3.0 KC1, 1.5 MgCl 2 , 1.5 CaCl 2 , 132 NaCl, 6.6 Urea, 3.7 Dextrose, and 24.6 NaHC0 3 per liter, pH 7.33, PC0 2 46 mmHg and P0 2 43 mmHg.
• the artificial CSF was warmed to 37-38 °C before application to the cerebral cortical surface.
• Pial arteries were observed with a television camera mounted on a dissecting microscope.
• Vascular diameter was measured from a video monitor connected the camera with a video microscaler (model VPA 550, For-A-Corp., Los Angeles, CA).
• Pial artery diameter small artery diameter 120- 160 micro meter; arteriole diameter 50-70 micro meter
• the window was flushed over 30 s with 1-2 ml CSF through the port connected into the side of the window.
• CSF samples were collected for cGMP analysis before and at 10 min after medication administration.
• We collected the cerebral cortical periarachnoid CSF by slowly infusing CSF into one port of the window and allowing the CSF to drip freely into a collection tube on the opposite port.
• sulpiride a dopamine receptor D2 antagonist: glibenclamide (100 nM), a KATP channel antagonist; iberiotoxin (100 nM, Sigma- Aldrich), a Kc a channel antagonist on pial artery response to salvinorin A, cromakalim( ⁇ M) and calcitonin-gene related polypeptide (10 nM, 1 ⁇ ), a KATP agonist, and NS 1619(10 ⁇ , ⁇ ⁇ ), a KCa channel agonist, were also determined.
• naloxone (1 mg/kg IV) and norbinaltorphimine 1 ⁇ topical administration, a kappa opioid receptor antagonist, on the response to the salvinorin A, methionine enkephalin (10 nM, 1 ⁇ ) and isoproterenol (10 nM, 1 ⁇ ), a beta adrenergic receptor agonist, were investigated. All tested drug solutions were made fresh on the day of use. Pial artery response to salvinorin A administrated every 2 minutes was recorded for 30 min to determine whether the sustained vascular dilatation could be achieved.
• CSF samples were collected for cGMP determination before and after salvinorin A administration with or without L-NNA and norbinaltorphimine pretreatment.
• Commercially available ELISA kits (Enzo Life Sciences International, Inc. Plymouth Meeting, PA) were used to quantify cGMP concentration.
• the dilation effect is observed immediately after salvinorin administration and the duration of dilation lasted less than 5 minutes for both doses.
• the salvinorin A was administration administered every 2 minutes, sustained dilation effects was observed as shown in Fig. IB.
• the dilation response was abolished by L-NNA, the NOS inhibitor, but not 7-nitroindazole (100 nM), the antagonist of neuronal NOS (nNOS) (Fig. 1A,C). Dilation response to SNP was not affected by L-NNA (Fig. 1A).
• Glibenclamide ( ⁇ ) but not iberiotoxin (100 nM) blocked the dilation in response to cromakalim (an agonist of KATP channel, 10 nM and 1 ⁇ ) and calcitonin-gene related polypeptide (another KATP channel agonist, 10 nM and 1 ⁇ ); iberiotoxin (100 nM) but not glibenclamide (lOOnM) blocked the dilation effects of NS1619 (KCa channel agonist, 10 nM and 1 ⁇ ) (Fig. 4).
• Opioid receptor not dopamine receptor D2 antagonist blocks dilation effect of salvinorin
• salvinorin A is demonstrated to be a potent pial artery dilator in piglet in normal and vessel constricted conditions induced by endothelin and hypocarbia.
• the dilatation effect was observed immediately after salvinorin administration, lasted less than 5 min for both tested doses, and was dose-dependent.
• Sustained dilation effects of salvinorin A was observed with continuous administration.
• the activation of the opioid receptor, NOS and KATP channel were involved in the signal pathway of such dilation effects.
• KOR agonist BRL 52537 Similar to other KOR agonists, the activation of NOS, KATP channels and opioid receptors mediated the dilation effects of salvinorin A. Another group has demonstrated that selective KOR agonist BRL 52537 protected the ischemia brain via attenuating nitric oxide production in ischemic striatum. It was proved that the neuroprotection of BRL 52537 was lost in nNOS null mice. Therefore, the KOR agonist BRL 52537 attenuated nNOS activity and ischemia-evoked nitric oxide production.
• KATP channels activation may result in hyperpolarization of the membrane of vascular smooth muscle cell. Membrane potential changes would then regulate muscle relaxation through alterations in Ca 2+ influx through voltage-dependent Ca 2+ channels.
• This Example demonstrates that salvinorin A activates the KATP channel directly or indirectly. Different from many other agents that can activate KATP channel, salvinorin A can easily penetrate the blood-brain barrier. Since the KATP channel plays a crucial protective role against brain injury from hypoxia, ischemia or metabolic inhibition, salvinorin A can be a neuro-protective agent for clinical use.
• the vascular dilative effect observed in normal and constricted cerebral vessels by both hypocarbia and endothelin can allow for its clinical application to treat cerebral vessel spasm in many clinical situations including migraine and cerebral vascular spasm after subarachnoid hemorrhage in which increase of endothelin plays an important role. Similar to other short acting agents, continuous infusion could be used to titrate and achieve sustained effects by adjusting dosage.
• salvinorin A is a fast and short acting potent pial artery dilator in piglet in normal and vessel constricted conditions induced by endothelin or hypocarbia.
• the mechanism involves the activation of NOS, KATP channel and kappa receptor.
• HIE moderate hypoxic-ischemic encephalopathy
• KOR agonists cause dilation of cerebral vessels, a key feature required to maintain cerebral autoregulation and reduce brain injury from ischemia. After ischemia, cerebral autoregulation is impaired, resulting in decreased cerebral blood flow and neuron death.
• ischemia cerebral autoregulation is impaired, resulting in decreased cerebral blood flow and neuron death.
• Salvinorin A (purity >98%) was obtained from ChromaDex, Inc. (Irvine, CA, USA). Isoproterenol (ISO), nor-binaltorphimine (Nor-BIN) were obtained from Sigma- Aldrich (MO, St. Louis, MO, USA). All other chemicals (reagent grade) were obtained from Sigma as well. Animal and Surgery for Closed Cranial Window
• a closed cranial window consisting of a steel ring with a glass cover slip, connecting to 3 ports, was placed for direct pial artery visualization and diameter measurement.
• Small pial arteries 120 to 160 ⁇
• arterioles 50 to 70 ⁇
• the ports attached to the cranial window ring fit 17-gauge hypodermic needles for CSF sampling, washout, and drug administration.
• Cortical periarachnoid CSF was collected at baseline and 60 min after HI for ERK activity analysis.
• DMSO group with DMSO (vehicle of salvinorin A) 1 ⁇ /kg administrated immediately after HI
• SA Omin group with salvinorin A(l ⁇ g/ ⁇ l in DMSO) 10 ⁇ g/kg immediately after HI
• SA 30min group with salvinorin A (1 ⁇ g/ ⁇ l in DMSO) 10 ⁇ g/kg 30 min after HI
• SA+Norbin group with salvinorin A (10 ⁇ g/kg) and nor-BIN (1 ⁇ , topically injected through one port of cranial windows) immediately after HI.
• Pial artery responses to hypercapnia, hypotension and isoproterenol (10 nM, 1 ⁇ ) were obtained before HI and 60 minutes after HI as previously described.
• Isoproterenol was used as a positive control since it is a short acting agent and its vascular dilatation effect in such model is well established in our lab.
• Two levels of hypercapnia (PaC0 2 of 50 to 60 mmHg for low level, 70 to 80 mmHg for high level) were produced by inhalation of high concentration C0 2 mixture gas (10% C0 2 ; 21% 0 2 ; 69% N 2 ).
• ERK activity were then determined from frozen CSF samples described above. The levels of pERK and ERK were measured by ELISA kits (Enzo Life Sciences International, Inc., Plymouth Meeting, PA).
• Salvinorin A preserves pial artery autoregulation to hypercapnia after global cerebral HI
• the small pial artery dilated in response to two levels of hypercapnia before HI (presented as baselines).
• the dilatation responses to hypercapnia were blunted after HI when DMSO was administrated immediately at the end of HI (ps ⁇ 0.01 as compared with the baselines before HI).
• Salvinorin A preserves pial artery autoregulation to hypotension after global cerebral HI
• the ERK activities are quantified as the ratio of pERK/ERK levels in CSF.
• the ERK activity data in groups without salvinorin effects (DMSO group and SA+Norbin group; renamed as DMSO+Nornin group) are combined.
• the ERK activity in groups without salvinorin increased significantly 60 min after HI (p ⁇ 0.05 as compared with pre-HI baseline).
• the ERK activity of salvinorin A administration groups reduced to the baseline level.
• KOR agonists have been demonstrated in other ischemia animal models.
• KOR agonist BRL 52537 and CI-977 reduces cortical damages, including brain swelling and infarction volumes, in response to different levels of ischemia when administrated 30 min before or up to 6 hours after the insult.
• KOR agonists exhibit tremendous therapeutic value, most KOR agonists have not been used in clinical settings because of their intrinsic characteristics as opioids, (low selectivity and/or lack of an acceptable safety profile).
• salvinorin A is the most potent, highly selective, and the only non-opioid KOR agonist known to be derived from natural sources.
• Salvinorin A is the active component of Salvia divinorum, a naturally abundant perennial herb that has been consumed by humans for recreational and sacred purposes for several centuries. Many intrinsic characteristics of this compound make it a potential therapeutic medication for various neurological conditions.
• Salvinorin A has been evaluated as a potential medication for depression. In addition to our findings demonstrating the protective effect of salvinorin A administration before HI insult, we have now demonstrated that salvinorin A administration (up to 30 min) after HI insult preserved the autoregulation of pial artery.
• ERK signaling stimulated by cerebral ischemia/reperfusion is a crucial pathway for HI injury.
• HI induced increases in the CSF ERK activities were blocked by salvinorin A, which promoted protection of cerebral autoregulation post insult. It is worth noting that the role of ERK signaling in HI may be different before and after HI insult. Activation of ERK signaling may be related to the protective effects of preconditioning.
• Salvinorin A pretreatment preserves cerebrovascular autoregulation after brain hypoxic/ischemic injury via ERK/MAPK in piglets
• Cerebral hypoxia/ischemia because of the interruption of cerebral blood flow during cardiopulmonary bypass with deep hypothermia circulation arrest (DHCA) surgery for congenital cardiac surgery is a significant clinical issue.
• Fifty percent of children with complex congenital heart disease undergoing cardiopulmonary bypass with DHCA have developmental deficits, such as disabilities in speech and attention deficit disorder by school age. Cerebral hypoxia /ischemia occurred during DHCA is predictable, thus, it is possible to minimize the brain injury induced by ischemia with pharmacologic approaches. Unfortunately, no pharmacological agent with proven clinical benefit has been identified yet.
• Loss of cerebral vascular autoregulation is one of the key features of cerebral hypoxia/ischemia.
• the loss of autoregulation to hypotension could result in a pressure passive cerebral circulation, which may decrease cerebral blood flow and further aggravate brain ischemia.
• Loss of cerebrovascular regulation to hypercapnia also contributes to the development of the pressure passive circulation and periventricular leukomalacia.
• preservation of cerebral vascular autoregulation from ischemia is very important to reduce the brain injury from ischemia.
• salvinorin A an active component of Salvia divinorum and a non-opioid kappa opioid receptor (KOR) agonist, is a potent cerebral vascular dilator in normal and pathological conditions.
• salvinorin A can protect cerebral vasculature from ischemia.
• salvinorin A has long been used by different ethnic groups for various purposes, including spiritual experiences and "treating" illnesses, indicating its high potential as a clinically acceptable medication.
• MAPK mitogen-activated protein kinase
• MAPK is a key intracellular signaling system, which includes extracellular signal regulated kinase (ERK), c-Jun-N-terminal kinase (JNK) and p38.
• ERK extracellular signal regulated kinase
• JNK c-Jun-N-terminal kinase
• p38 extracellular signal regulated kinase
• ERK extracellular signal regulated kinase
• JNK c-Jun-N-terminal kinase
• p38 extracellular signal regulated kinase
• ERK extracellular signal regulated kinase
• JNK c-Jun-N-terminal kinase
• p38 extracellular signal regulated kinase
• ERK extracellular signal regulated kinase
• JNK c-Jun-N-terminal kinase
• p38 extra
• Salvinorin A (purity >98 ) is from ChromaDex, Inc. (Irvine, CA, USA). Isoproterenol, U0126, sp600125 and sb203580 are obtained from Sigma-Aldrich (MO, St. Louis, MO, USA). All other chemicals were also obtained from Sigma and were of reagent grade.
• a closed cranial window was placed for direct pial artery visualization and diameter measurement (21).
• Small pial artery (120 to 160 ⁇ ) and arteriole (50 to 70 ⁇ ) are identified under microscope, visualized on a monitor connected to the microscope, and measured via a video microscaler (model VPA 550, For-A-Corp., Los Angeles, CA).
• the cranial window is a steel ring with a glass cover slip, connecting to three ports for cerebrospinal fluid (CSF) sampling, washout and medicine administration.
• CSF cerebrospinal fluid
• Cortical periarachnoid CSF was collected through one of the above ports at baseline and 30 minutes after administration of salvinorin A or U0126 plus salvinorin A for ERK/MAPK analysis.
• sp600125 and sb203580 are administrated 30 minutes before salvinorin A.
• Sp600125 and sb203580 were co-administered with the vasoactive stimulus so as to have continued exposure of the cerebral cortical surface after injury.
• Hypercapnia (PaC0 2 of 50 to 60 mmHg for low level, 70 to 80 mmHg for high level) was produced by inhalation of high concentration C0 2 mixture gas (10% C0 2 ; 21% 0 2 ; 69% N 2 ). Hypotension was produced by withdrawing blood from the femoral artery (25% decrease in mean blood pressure as moderate and 45% as severe). Pial artery responses to hypotension, hypercapnia, and isoproterenol (10 nM, ⁇ ) were obtained before hypoxia/ischemia and 60 minutes after injury as described previously.
• MAPK isoforms were measured by commercially available ELISA kits (Enzo Life Sciences International, Inc., Plymouth Meeting, PA).
• Salvinorin A preserved pial artery autoregulation to hypotension after hypoxia/ischemia.
• Salvinorin A preserved pial artery autoregulation to hypercapnia after hypoxia/ischemia.
• cerebrovascular dysfunction plays a very important role in neurological insult after hypoxia/ischemia.
• the only medication approved by the Food and Drug Administration for stroke is recombinant tissue plasminogen activator (tPA).
• tPA tissue plasminogen activator
• L-NNA an inhibitor of nitric oxide synthesis, was proven to be able to restore cerebral vascular auto regulation administrated after ischemia, however, its safety profile is unclear for clinical usage.
• salvinorin A pretreatment preserved the autoregulatory responses to hypotension and hypercapnia after hypoxia/ischemia in a piglet model, which opens its clinical applications to attenuate cerebral hypoxia/ischemia, especially for anticipated brain ischemia during DHCA in infant. More studies are needed to provide direct evidence to demonstrate whether it could attenuate neuronal cell injury from hypoxia/ischemia.
• salvinorin A is extracted from an abundant natural plant, Salvia divinorum. Very similar to the history of opium, Salvia divinorum as a naturally abundant plant has been used by human beings for various purposes, for centuries. It has been proposed that salvinorin A, the active component of Salvia Divinorum, could be a potential new kappa agonist to be used in clinical practice.
• Salvinorin A is a potent cerebral vascular dilator in normal and constricted conditions as we have demonstrated. However, this dilatation effect is short lived unless with continued administration; thus, the preservation of autoregulation is unlike induced from the dilatation effects since salvinorin was administrated 30 min prior hypoxia/ischemia.
• MAPK has been proven to be important in signal transduction from the cell surface to the nucleus. Elevation of ERK/MAPK before ischemia is related to neuronal survival after ischemia(15). Activation of ERK/MAPK in the hippocampal CA1 region after sublethal ischemia correlates with neuroprotection induced by preconditioning.
• Exercise preconditioning reduces neuronal apoptosis in stroke by up-regulating ERK/MAPK.
• pERK/ERK in CSF increased significantly 30 minutes after administration of salvinorin A, indicating the activation of ERK and also suggesting that salvinorin A might be vascularly or neuronally protective when administered prior to brain ischemia.
• elevation of ERK/MAPK in the immediate post injury reperfusion period is associated with impairment of responses to cerebrovasodilators as well as histopathology after hypoxia/ischemia in the piglet (32).
• the reason for the observed duality of ERK/MAPK function is uncertain but may relate to the cellular site of origin, signal coupling, or temporal pattern of release.
• Newborn piglets used in this Example offer the unique advantage of a gyrencephalic brain containing substantial white matter, which is more sensitive to ischemic damage than rodent brain, and more similar to humans.
• salvinorin A pretreatment preserved cerebrovascular autoregulation to hypotension and hypercapnia after brain hypoxia/ischemia via ERK/MAPK in a piglet model.
• Salvinorin as an adjunctive medication for difficult airway mana2ement
• salvinorin can be useful during awake intubation.
• salvinorin is poorly soluble in water.
• One option is to use its salt form to increase water solubility, and the other is to use lipid emulsion. Both techniques are readily available and have been successfully used for other anesthetic drugs in the perioperative settings.
• Cucurbituril (Fig. 11) could be used as a carrier. As shown in Figures 12-13, a complex of salvinorin and cucurbituril can be used.
• Salvinorin A decreases mortality and improves neurolo2ical outcome in a neonatal mouse hypoxia model
• Neonatal hypoxic -ischemic (HI) injury can induce high mortality and lifelong catastrophic neurologic and neuro-developmental deficits that include epilepsy, learning disabilities, and behavioral disorders.
• therapeutic hypothermia along with supportive treatment is considered the only effective approach.
• well-controlled hypothermia can only be applied to highly selected patient populations in well-established facilities and it can only produce an outcome improvement of only about 30% in asphyxiated infants. It requires extensive training and multidisciplinary collaborations.
• therapeutic hypothermia can be dangerous, leading to an increased incidence of mortality, multiple organ failure, sudden cardiac arrest, pulmonary hypertension, and bleeding.
• there is a significant medical need to develop a novel medication and/or easily manageable therapeutic strategy to reduce neuronal injury from cerebral HI in the perinatal period.
• SA Salvinorin A
• KOR kappa opioid receptor
• SA could be a potential medication for brain protection for neonates.
• SA does not produce dysphasia and its intrinsic characteristics make it an ideal therapeutic candidate for various neurological conditions. These characteristics include: rapid onset, easy passage to the central nervous system, antinociceptive and sedative effects, no negative pathological changes in organs following prolonged or high dose exposure, and no respiratory depressive effect. Although the compound has been reported to have hallucinogenic activity, such effects are short-lived and do not produce blood pressure and heart rate changes or cognition impairment. In a recent human study, no persisting adverse effects related to SA were observed.
• Salvinorin A (purity >98%) was obtained from Apple Pharms (Asheville NC, USA). All other chemicals (reagent grade) were obtained from Sigma- Aldrich (MO, St. Louis, MO, USA).
• hypoxic insult was induced on postnatal day 1. After i.p. injections, pups were put into a glass chamber in a water bath where the temperature was maintained at 37°C. The chamber was tightly closed and filled with 8% oxygen with balanced nitrogen. Following 120 minutes of hypoxic gas exposure, the chamber was opened and the pups were exposed to the air. Chest compressions and limb stretches were performed for up to 20 minutes to regain spontaneous breathing. The pups that successfully regained spontaneous breathing were then returned to their mothers after recovery for 30 minutes. Mortality rate determination
• the neonate mouse will be considered as non-survival if no spontaneous breathing can be restored for 20 min resuscitation immediately after anoxic insult.
• mice were tested in several behavioral tasks in the order of: zero mazes, barnes maze and fear conditioning. These tasks were performed to examine the basal anxiety level, spontaneous locomotor activity, motor learning, spatial learning and associative memory of the mice. The mice were given 5 days for rest between each behavioral test.
• Zero Maze anxiety-like behavior: "Time in open” measures mice anxiety due to their tendency to avoid open spaces. The anxiety was measured by recording the time spent in the open vs. enclosed space. Increased anxiety correlates to decreased time in the open. Open/Closed transitions measure overall activity. Increased transitions equate to greater activity.
• Barnes Maze spatial learning: Measures the ability to learn with visual cues. Time to Target measures the time taken to find the target hole in an arena with 19 other holes and several visual cues. The Barnes Maze is easier to set-up and probably less stressful and a valid alternative to the Water Maze to study spatial memory. One of the advantages of the Barnes maze task was that it was not influenced by stress as much as other similar tasks and no strong aversive stimuli or deprivation were used.
• Fear Conditioning (memory): Training trial freezing, short term contextual freezing, long term contextual freezing and cued trial freezing were recorded to examine and assess the memory deficits after hypoxia injury.
• there was no statistical significance with other developmental parameters such as crawling ( Figure 24A), walking (Figure 24B), running (Figure 24C), head point and sniffing (Figure 24D), sitting (Figure 24E), rearing with support (Figure 24F) negative geotaxis test (Figure 24G) and placing reflex (Figure 24H), though hypoxic pups also showed delayed appearance compared to both the control and SA groups.
• Intranasal Salvinorin A reduces infarct size and improves neurolo2ical outcome in a mouse stroke model
• Salvinorin A is the only known naturally occurring non-opioid KOR agonist that has been consumed by humans for centuries with a known safety profile. It has a rapid onset (within minutes) when delivered either via mucosa or inhalation. SA intranasal can be performed quickly in acute settings where intravenous (IV) access is unavailable (which is very common for out-of -hospital cardiac arrest events). A major barrier for effective therapies for ischemic stroke is how quickly the medication can be delivered to the patient. While IV administration ensures quick onset, IV access is generally not available in an out-of-hospital situation. Oral administration generally requires more than 30 min for pharmacological effects to be achieved. Thus, rapid therapeutic delivery intranasal would make SA an extremely practical and favorable medication for treating brain hypoxia/ischemic events.
• FIG. 29 depicts the protocol used. Briefly, a middle cerebral artery occlusion (MCAO) was induced in the mice and the indicated dose of salvinorin A in DMSO was administered intranasally. The mouse was reperfused for 24 hours after which the mice were euthanized and infarct size and vascular leakage was measured. Salvinorin A administration demonstrated dose-dependent improvements in motor function as measured by a grip strength score ( Figure 30) and neurobehavior ( Figure 31).
• MCAO middle cerebral artery occlusion
• Intranasal administration of salvinorin A also led to a dose-dependent reduction (except that the protective effect was diminished at a dose of 250 ⁇ g/kg) in infarct size as can be seen by the reduction of white infarcted area in TTC stains of the brain ( Figures 32 and 33).
• Evans blue extravasation indicated blood brain barrier disruption and vascular leakage after ischemia and reperfusion of the brain.
• Intranasal salvinorin A administration reduced the disruption and leakage, while the administration of the kappa receptor antagonist Norbinaltorphimine (norbin) inhibited the protective effect of salvinorin A (Figure 34).
• Intranasal salvinorin A improves overall motor function as shown in Figure 35.
• the mouse that has not been administered salvinorin A (the mouse on the ground) cannot walk normally since the left side was paralyzed 24 hours after the MCAO; the mouse that has been administered intranasal salvinorin A (the mouse on the string) can crawl over a hanging string.
• Herkinorin is the first non-opioid mu agonist derived from the structurally related compound salvinorin A. Since kappa opioid receptor activation elicits pial artery dilation and salvinorin A is a potent cerebral vasculature dilator that activates nitric oxide synthases, kappa receptors, and adenosine triphosphate-sensitive potassium channels, it is likely that herkinorin could also elicit cerebrovasodilation. Herkinorin has an approximately 8-fold selectivity for mu over kappa receptors and an approximately 98-fold selectivity for mu over delta receptors in competition binding assays. Thus, it is important to elucidate whether its mu agonism plays any role in the cerebral vasculature effects for compounds from this category due to their potential clinical implications as non-opioid receptor agonist.
• cAMP is a key modulator downstream of opioid receptors (Liu and Anand, 2001) and activation of cAMP signaling elicits vascular smooth muscle relaxation, resulting in cerebrovasodilation in the pig brain.
• opioid receptor antagonists attenuated cAMP analog -induced pial, suggesting a potential connection between cAMP- mediated and opioid-mediated vasodilations. It is possible that herkinorin could induce cerebral vascular dilation via the cAMP pathway.
• herkinorin the first non-opioid mu agonist derived from salvinorin A, could dilate cerebral vasculature via mu and kappa opioid receptors and cAMP pathway. This hypothesis is distinctive from our previous study related to salvinorin A since herkinorin is categorized as a mu receptor agonist despite its structural similarity to the highly selective kappa opioid receptor agonist salvinorin A.
• Herkinorin (purity >99 ) was obtained from Ascent Scientific LLC (Cambridge, MA, USA). Isoproterenol, NTP, ⁇ -FNA, Rp-cAMPS and Sp-8-Br-2'-0-Me-cAMPS (Sp-cAMPS) were purchased from Sigma-Aldrich (St. Louis, MO, USA). All other chemicals were of reagent grade and were obtained from Sigma as well.
• the top tanked pose of the docking results were used to compare the overlapping of the ligand for each receptor.
• PyMOL http://www.pymol.org/, Version 1.3, Schrodinger, LLC
• Newborn pigs (aged up to 6 days, 1.1-2.0 kg) of both genders were used for this study. Protocols were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania (Philadelphia). The newborn piglet model was used because its brain is gyrencepahalic and contains more white matter than grey matter, which is similar to that of humans. Furthermore, the head is large enough for the insertion of a cranial window and vascular visualization. Animals were induced with isoflurane (1-2 minimum alveolar concentration) and maintained with a-chloralose (80-100 mg/kg supplemented with 5 mg /kg-h, IV).
• Both femoral arteries were catheterized to monitor blood pressure and blood gas to maintain a constant carbon dioxide and pH.
• a catheter was inserted into the right femoral vein for medication administration. Animals were ventilated with room air after tracheal intubation. A heating pad was used to maintain the rectal temperature of animals at 37-39 °C.
• a closed cranial window on the top of the head of the piglet was placed for direct pial artery visualization and diameter measurement.
• the closed cranial window consisted of three parts: a stainless steel ring, a circular glass cover slip, and three ports consisting of 17-gauge hypodermic needles attached to three precut holes in the stainless steel ring. CSF was collected through a cranial window port for cAMP measurement in some animals.
• the space under the window was filled with artificial CSF with the following composition (in mM): 3.0 KC1; 1.5 MgCl 2 ; 1.5 calcium chloride; 132 NaCl; 6.6 urea; 3.7 dextrose; 24.6 NaHC0 3 ; pH 7.33; PaC0 2 , 46 mmHg; and P0 2 43 mmHg.
• Artificial CSF was warmed to 37-38 °C before applying to the cerebral cortical surface.
• Pial arteries were observed with a video camera mounted on a dissecting microscope.
• Vascular diameter was measured from a video monitor that was connected to the camera with a video microscaler (VPA 550; For-A-Corp., Los Angeles, CA) by the investigator who administered the medication.
• the binding site of herkinorin overlaps with that of ⁇ -FNA, a selective mu opioid receptor ligand in the crystal structure shown in figure 36B.
• the binding affinity of herkinorin to mu receptor is approximately 4-fold stronger than that to kappa receptor.
• Herkinorin induced kappa receptor-dependent vasodilation upon administration Herkinorin induced kappa receptor-dependent vasodilation upon administration.
• the pial artery diameters increased after herkinorin administration without significant systemic blood pressure variation. Applying 0.1 nM herkinorin induced a 10.6% diameter dilation while 10 nM herkinorin induced a 17.8% diameter dilation on average. The dilation effects were totally abolished by norbinaltorphimine (NTP), a kappa receptor antagonist (figure 38A, Ps ⁇ 0.05 compared with herkinorin administration groups), but not affected by ⁇ -FNA (figure 38B). Isoproterenol-induced pial artery dilation was unchanged by either NTP or ⁇ -FNA. ⁇ -FNA itself elicited minimal pial artery dilation (P ⁇ 0.05, Dunnett's multiple comparison tests). These results indicate that the herkinorin-induced vasodilation is mediated via kappa, but not mu opioid receptor.
• Pial artery dilation by herkinorin was mediated via cAMP signaling.
• herkinorin is a potent pial artery dilator despite its classification as a non-opioid mu receptor agonist.
• the herkinorin- induced pial artery dilation effects are modulated via kappa opioid receptors. No significant involvement of the mu opioid receptor is observed.
• cAMP is demonstrated to be involved in the kappa agonist induced cerebral vascular dilatation previously. This study also confirms previous findings that herkinorin interacts with both mu and kappa opioid receptors and the binding site for this interaction overlaps with that of other traditional opioid receptor ligands. Discussion
• Herkinorin as a non-nitrogenous opioid receptor agonist
• herkinorin is an opioid receptor agonist, it does not contain nitrogen, an essential element for the traditional nitrogenous opioid ligand. Thus, herkinorin is the first non- opioid mu opioid receptor ligand.
• Herkinorin was discovered in 2005 when various analogues of the natural product Salvinorin A were synthesized to study the structure and the function of neoclerodane diterpenes. While salvinorin A is a selective kappa opioid agonist with no significant mu opioid receptor affinity, herkinorin acts on both mu and kappa receptors. Its affinity for the mu receptor is much stronger than that for the kappa receptor as demonstrated here and in other studies. Thus, unlike salvinorin A, herkinorin is categorized as a mu opioid receptor ligand. Its binding site overlaps well with the sites for other receptor ligands as demonstrated in the docking experiments.
• herkinorin does not induce ⁇ -arrestin recruitment or promote receptor internalization suggests that herkinorin may not induce significant tolerance or dependence as traditional opioids do.
• a recent study indicates that herkinorin could produce a dose-dependent antinociceptive effect in a rat pain model, suggesting that herkinorin may be a promising starting point for developing novel analgesics without significant risk of dependence or tolerance.
• herkinorin exhibits similar pharmacological features for cerebral vasculature to salvinorin A as we demonstrated previously.
• Herkinorin seems to be a more potent artery dilator than salvinorin A because the concentration required to effectively dilate pial arteries (10 -16 % changes compared to the baseline) is much lower for herkinorin (0.1 nM) compared to that of salvinorin A (10 nM).
• the cerebro vasodilation effect of herkinorin is blocked by NTP, but not ⁇ -FNA. Similar to our previous study, neither NTP nor ⁇ -FNA shows any effect on pial diameter by itself.
• the cerebral vascular dilatation effects of herkinorin are mediated through the kappa opioid receptor rather than the mu receptor.
• Cerebro vasodilation is mediated through several mechanisms, including cGMP, cAMP, and K+ channels.mlsoproterenol and cAMP increase the activities of calcium-dependent potassium channels in the cerebral vascular muscle, which is believed to induce vasodilatation.
• cerebrovasodilation is associated with the elevation of cAMP levels in the CSF after administration of herkinorin.
• the cerebrovasodilation induced by herkinorin administration is abolished by the cAMP antagonist Rp-cAMPS.
• salvinorin A could dilate cerebral vasculature and preserve cerebral autoregulation from cerebral hypoxia/ischemia injury in a piglet model, it is highly likely that herkinorin has similar properties given that its cerebrovasodilative effects are modulated in a manner similar to salvinorin A. Thus, it can be an alternative non-opioid medication to be used during the perioperative period for patients who are at risk for cerebral vascular spasm or ischemia.
• Salvinorin A treats subarachnoid hemora2e
• Salvinorin A is a very hydrophobic molecule and is insoluble in water. Salvinorin A is soluble in known to be soluble in organic solvents like ethanol, DMSO, and acetone. However, these solvent are not suitable for routine clinical use, especially for intravenous (IV) delivery. Since salvinorin A is usefull clinically, for neurological disorders, there is a need to identify materials, preferably FDA approved materials, which can be used to formulate salvinorin A for clinical delivery. Physical and chemical properties of salvinorin are presented in Table 1 below.
• Salvinorin A cannot form soluble salts.
• Salvinorin A has eight hydrogen-bond acceptor sites, all oxygen atoms, and no hydrogen-bond donor groups. It would thus appear likely that its crystal lattice should comprise only weak non-bonded interactions between adjacent molecules and a resultant diminished lattice energy reflected in a low melting point.
• salvinorin A has a rather high melting point range reported as 238-240 °C.
• An x-ray crystal structure of SA revealed that crystallization from aqueous organic solvents (acetone, methanol) yields SA as a stoichiometric hydrate with one molecule of water per three molecules of salvinorin A.
• HPGCD 2-Hydroxypropyl-y-cyclodextrin
• Salvinorin A is only minimally soluble in water and either a-cyclodextrin sulfated sodium salt or ⁇ -cyclodextrin sulfated sodium salt.
• HPBCD demonstrated solubility of salvinorin A with a maximum concentration of more than 100 ⁇ g/mL.
• HPBCD can be used to formulate 50 ⁇ g/mL of salvinorin A, which is equivalent to the clinical dose for fentanyl.
• there is a significant solubility difference between HPBCD and HPGCD as indicated in Table 2, i.e., 122.5 + 0.6 ⁇ g/mL in 20% HPBCD vs. 52.6 + 0.9 ⁇ g/mL in 20% HPGCD.
• Salvinorin A solubility in other solvents is presented in Table 3. Table 2. Solubility of Salvinorin A in various cyclodextrins
• HPBCD is a FDA approved material for IV drug delivery in clinical practice.
• voriconazole VFEND®, Pfizer
• Sulfobutylether ⁇ -cyclodextrin for IV delivery.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Inorganic Chemistry (AREA)
• Otolaryngology (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicines Containing Plant Substances (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (2)

Family

ID=54145490

Family Applications (1)

Country Status (4)

Cited By (3)

Citations (2)

Family Cites Families (6)

• 2015
  • 2015-03-23 EP EP19210883.5A patent/EP3685843A3/en not_active Withdrawn
  • 2015-03-23 EP EP15765744.6A patent/EP3119411B1/en active Active
  • 2015-03-23 JP JP2016558399A patent/JP2017508768A/ja active Pending
  • 2015-03-23 CN CN201580026976.9A patent/CN106604737B/zh active Active
  • 2015-03-23 WO PCT/US2015/021994 patent/WO2015143429A2/en not_active Ceased
• 2019
  • 2019-12-02 JP JP2019217715A patent/JP2020045359A/ja active Pending

Patent Citations (4)

Non-Patent Citations (13)

Also Published As

Similar Documents

Legal Events